Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 4, 2025
Better Choice Company Chairman Provides Shareholder Update on SRx Health Acquisition and Comments on Recent Debt-to-Equity Transaction
GlobeNewswire
·
April 4, 2025
TAMPA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, Chairman, Michael Young, today provides shareholders with a update on its SRx Health …
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
GlobeNewswire
·
April 4, 2025
LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive …
Medical Filtration Market worth $9.35 billion by 2030, at a 6.8%, says MarketsandMarkets™
GlobeNewswire
·
April 4, 2025
Delray Beach, FL, April 04, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Medical Filtration Market Is projected to reach USD 9.35 billion by 2030 at a CAGR of 6.8%, as per the recent study by MarketsandMarkets™. The combination of regulatory frameworks, …
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
GlobeNewswire
·
April 4, 2025
TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“NurExone” or the “Company”) is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non- …
Better Choice Company Signs Definitive Agreement for SRx Health Solutions to Convert CAD$4 Million in Debt to Equity
GlobeNewswire
·
April 4, 2025
TAMPA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, is pleased to announce that SRx Health Solutions, Inc. (“SRx Health”) has signed a …
Dental Equipment Market worth US$9.3 Billion by 2029 driven by Specialized Dental Equipment | MarketsandMarkets™.
GlobeNewswire
·
April 4, 2025
Delray Beach, FL, April 04, 2025 (GLOBE NEWSWIRE) -- The global dental equipment market , valued at US$6.5 billion in 2023, is forecasted to grow at a robust CAGR of 6.2%, reaching US$6.9 billion in 2024 and an impressive US$9.3 billion by 2029. The dental …
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
GlobeNewswire
·
April 4, 2025
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resistant …
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
GlobeNewswire
·
April 4, 2025
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meeting Long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS) Exploratory analysis of efficacy of …
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock
GlobeNewswire
·
April 4, 2025
EDEN PRAIRIE, Minn., April 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological …
Entourage Health Corp. Announces Closing of Plan of Arrangement
GlobeNewswire
·
April 4, 2025
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (the “Company” or “Entourage”) is pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) pursuant to …
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
GlobeNewswire
·
April 4, 2025
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory …
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
GlobeNewswire
·
April 4, 2025
PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today …
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 4, 2025
DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of …
EluPro™ Named as 2025 Edison Award Winner
GlobeNewswire
·
April 4, 2025
Innovative Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Pacemakers and Neurostimulators Earns Bronze in Post-Surgical Recovery Solutions Category SILVER SPRING, Md., April 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia …
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 4, 2025
WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare …
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
GlobeNewswire
·
April 4, 2025
MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of …
Best Cutting and Bulking Steroids - Buy Oral Steroid Stacks for Muscle Gain, Fat Loss and Strength from CrazyBulk
GlobeNewswire
·
April 4, 2025
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Using steroids for bodybuilding is typically divided into two distinct phases: the bulking phase and the cutting phase. Each phase has specific goals—bulking focuses on gaining muscle mass and strength, while …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 4, 2025
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on …
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
GlobeNewswire
·
April 4, 2025
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers – – Findings support continued …
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 4, 2025
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees restricted stock units (RSUs) …